ClinicalTrials.gg
RecruitingNCT05515367Updated Jan 22, 2025

A Post Marketing Surveillance to Evaluate the Safety of Desidustat for the Treatment of Anemia in Subjects With Chronic Kidney Disease (CKD).(Real World Evidence Study)

A Phase 4 interventional study of Desidustat in Chronic Kidney Diseases and Anemia of Chronic Kidney Disease, sponsored by Zydus Lifesciences Limited. Recruiting at 1 site in India. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by Zydus Lifesciences Limited · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,004
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies in Renal Insufficiency, Chronic with a site in India — 18 open to participants now, 25 under way, 15 of them phase 3. Renal Insufficiency, Chronic · India.

Planned enrollment
21st of 54
1,004 · median 570
Started
2023
with 7 others
Phase 4
5 of 64
2 open now
Primary completion
2025-06
later than 1 of 24 live
Registered
36th of 64
by date

Among the 64 studies in Renal Insufficiency, Chronic with a site in India, this one is the 21st largest by planned enrollment of the 54 interventional ones that give a count, is one of 8 that started in 2023, is one of 5 in phase 4, reaches primary completion later than 1 of the 24 other live ones, and was the 36th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

18 of the 64 studies in Renal Insufficiency, Chronic with a site in India are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Renal Insufficiency, Chronic with a site in India, or all of them as a file.
02

Study summary

A Phase 4, 52 week, single arm, multicentre post marketing surveillance to evaluate the safety of Desidustat for the treatment of anemia in subjects with chronic kidney disease (CKD)

Read the detailed description

The study is being planned to evaluate long term safety of Desidustat with CKD patient.

Total 1004 population i.e 502 dialysis dependent, 502 dialysis independent.

03

Conditions studied

  • Chronic Kidney Diseases
  • Anemia of Chronic Kidney Disease

Keywords

  • Real World Evidence Study
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, ≥ 18 years of age.
  2. Current clinical diagnosis of anemia due to CKD, baseline concentrations must be 7.0-11.0 g/dL (both inclusive) before the enrolment.
  3. Ability to understand and give for participation.
  4. No significant folate or Vitamin B12 deficiency.
  5. Females of , must agree to use one of the approved methods, from screening until End-of-study visit.
  6. For Subjects dependent on hemodialysis:

    1. Must be receiving haemodialysis session ≥2 times in a week for at least 12 weeks prior to screening visit and have access consisting of an arteriovenous fistula, AV graft, or catheter (permanent/temporary).
    2. Subjects will be considered not treated with erythropoietin analogue (Epoetin and Darbepoetin) if they have not received erythropoietin analogue for at least 4 weeks and Mircera® for at least 8 weeks prior to screening visit. OR Subjects who are on ESA therapy must be on stable dose for 4 weeks prior to enrolment (≤30% of dose change).

Exclusion criteria

Exclusion Criteria:

  1. Subjects who received red blood cell transfusion within 8 weeks prior to enrolment.
  2. Pre-dialysis subjects, who had prior exposure to ESA agents within 6 weeks prior to enrolment.
  3. In case of diabetes mellitus subjects, glycosylated () > 9 %.
  4. In case of hypertensive subjects, systolic and diastolic BP (Blood pressure) is >160 and 100 mm of Hg respectively or uncontrolled blood pressure.
  5. History of previous or concurrent cancer or renal transplant or severe allergic or to products and its or chronic inflammatory disease (RA, Celiac disease, UC, Crohn's disease, Systemic Lupus Erythematosus [SLE]).
  6. Serologic status reflecting active Hepatits B or C infection or (HIV) infection.
  7. History of uncontrolled haemolytic anemia, idiopathic thrombocytopenic purpura (ITP) or thalassemia/bleeding disorders or clinical conditions (e.g. gastrointestinal [GI] bleeding or constitutional disorders) that may increase risk of life-threatening bleeding./ requires or is receiving anticoagulation with warfarin or equivalent vitamin K antagonists or other medications within 28 days of the first dose of study drug that in the investigator's opinion, could compromise subject safety.
  8. Major surgery within 90 days and minor surgery within 30 days prior to the enrolment of the subject.
  9. Unable to swallow tablets or disease significantly affecting gastrointestinal function and/or inhibiting small intestine absorption such as; mal-absorption syndrome, resection of the small bowel or poorly controlled inflammatory bowel disease affecting the small intestine.
  10. History of myocardial infarction or stroke or intracranial haemorrhage within 6 months prior to enrolment.
  11. Currently active cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, any class 3 or 4 cardiac disease as defined by the (New York Heart Association) classification.
  12. Current life-threatening illness, medical condition, systemic disorders (e.g., respiratory, gastrointestinal, endocrine, immunological, dermatological, neurological, psychiatric disease or any other body system involvement) or laboratory abnormalities which, in the Investigator's opinion, could compromise the subject's safety.
  13. History of significant alcoholism or drug abuse within the past 1 year. History or presence of significant smoking (more than 10 cigarettes per day) or consumption of tobacco/nicotine products (more than 10 times per day).
  14. History of difficulty with donating blood.
  15. History or presence of any clinically significant abnormalities during screening.
  16. Participants who have participated in any drug research study other than the present trial within past 3 months.
  17. Female volunteers with following criteria will not be eligible:

    1. History of pregnancy or lactation in the past 3 months.
    2. Fertile female volunteers not protected against pregnancy by adequate long-term anti-fertility measures.
    3. History of less than 1 year of menopause and not using adequate long-term antifertility measures.
    4. Oral hormone replacement therapy.
    5. Positive serum β-hCG level at the screening visit.
    6. Pregnant and breastfeeding women.
  18. Abnormal baseline laboratory investigations as follows:

    1. WBC count ≤3 x 103/μL.
    2. count ≤100 x 103/μL.
    3. ≥2.0 mg/dL.
    4. and/or AST ≥2.5 times of the .
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,004 participants (estimated)

Study arms

  • Experimental
    Desidustat oral tablet

    Oral administration of Desidustat from baseline (week 0) to Week 52

    Drug: Desidustat

Interventions

06

What researchers measure

Primary outcomes

  1. To asses the Proportion of Subjects with treatment emergent adverse events.

    Time frame: Baseline (week 0) to Week 52 (end of treatment)

  2. To asses the Proportion of Subjects with treatment emergent Serious adverse events.

    Time frame: Baseline (week 0) to Week 52 (end of treatment)

Secondary outcomes

  1. Mean change in hemoglobin level

    Time frame: Baseline (week 0) to Week 52 (end of treatment)

  2. Mean change in Lipid profile including Small dense LDL from baseline

    Time frame: Baseline (week 0) to Week 52 (end of treatment)

  3. Mean change in VEGF

    Time frame: Baseline (week 0) to Week 52 (end of treatment)

  4. Mean change in serum Hepcidin

    Time frame: Baseline (week 0) to Week 52 (end of treatment)

07

Study locations

1 of 1 sites recruiting
  • Indira Gandhi Institute of Medical Sciences
    Sheikhpura, Bihar 800014, India
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jun 2025, 26 months after the start.

Of 117 phase 4 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 65. This study's planned 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2022
First posted
Aug 25, 2022
StartActual
Apr 20, 2023
Primary completionEst.
Jun 30, 2025
CompletionEst.
Nov 30, 2025
Last update
Jan 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05515367
Responsible party
Sponsor
First posted
Aug 25, 2022
Start date
Apr 20, 2023
Primary completion
Jun 30, 2025 (estimated)
Completion
Nov 30, 2025 (estimated)
Last update
Jan 22, 2025

Study contacts

Dr Kevin Kansagra, MD
Contact
kevinkumarkansagra@zyduslife.com
02717-665555 ext. 451
Dr. Deven Parmar, MD,FCP
study chair · Zydus Therapeutics Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Desidustat

Start the discussion